The TRACK trial: Improving cardiovascular health of chronic kidney disease patients with blood-thinning medication
- Patients with advanced stages of chronic kidney disease, including those receiving life-sustaining dialysis, have a significant burden of diseases relating to the heart and blood vessels, known as vascular disease, which shortens their life and reduces quality of life.
- Blood-thinning medications are used to prevent blood clots in people with heart and vascular disease, but these medications increase the risk of severe bleeding.
- Due to the increased dangers of both clotting of blood vessels and severe bleeding, treating patients with blood-thinning medications is challenging.
- TRACK aims to evaluate whether low-dose use of the blood-thinning medication, rivaroxaban, reduces the risk of death and major events due to heart and vascular disease, such as heart attacks and strokes, with an acceptable bleeding risk.
- TRACK is a randomised controlled trial that will enrol 1,972 patients from seven countries with advanced stages of chronic kidney disease, including those receiving dialysis, who also have existing heart or vascular disease.
- Participants will be randomly assigned to receive either low-dose rivaroxaban or a placebo, in the form of identical tablets.
- Neither doctors nor participating patients will know which treatment they have been assigned